Endocrinology and Metabolism

Original Articles

Thyroid
Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves’ Disease: A Retrospective Multicenter Study: Jee Hee Yoon, Meihua Jin, Mijin Kim, A Ram Hong, Hee Kyung Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Ho-Cheol Kang; Endocrinol Metab. 2021;36(6):1268-1276. Published online November 26, 2021; DOI: https://doi.org/10.3803/EnM.2021.1227

4,772 View
184 Download
10 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The association between Graves’ disease (GD) and co-existing thyroid cancer is still controversial and most of the previously reported data have been based on surgically treated GD patients. This study investigated the clinicopathological findings and prognosis of concomitant thyroid cancer in GD patients in the era of widespread application of ultrasonography.
Methods
Data of GD patients who underwent thyroidectomy for thyroid cancer between 2010 and 2019 in three tertiary hospitals in South Korea (Asan Medical Center, Chonnam National University Hwasun Hospital, and Pusan National University Hospital) were collected and analyzed retrospectively. In the subgroup analysis, aggressiveness and clinical outcomes of thyroid cancer were compared nodular GD and non-nodular GD groups according to the presence or absence of the thyroid nodules other than thyroid cancer (index nodules).
Results
Of the 15,159 GD patients treated at the hospitals during the study period, 262 (1.7%) underwent thyroidectomy for coexisting thyroid cancer. Eleven patients (4.2%) were diagnosed with occult thyroid cancer and 182 patients (69.5%) had microcarcinomas. No differences in thyroid cancer aggressiveness, ultrasonographic findings, or prognosis were observed between the nodular GD and non-nodular GD groups except the cancer subtype. In the multivariate analysis, only lymph node (LN) metastasis was an independent prognostic factor for recurrent/persistent disease of thyroid cancer arising in GD (P=0.020).
Conclusion
The prevalence of concomitant thyroid cancer in GD patients was considerably lower than in previous reports. The clinical outcomes of thyroid cancer in GD patients were also excellent but, more cautious follow-up is necessary for patients with LN metastasis in the same way as for thyroid cancer in non-GD patients.

Citations

Citations to this article as recorded by

Comparison of Surgical Outcomes of Transoral Versus Open Thyroidectomy for Graves Disease
Suo-Hsien Wang, Wu-Po Chao, Ta-You Lo, Soh-Ching Ng, Yu-Hsien Chen
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 150. CrossRef
Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu, Jiqi Yan
Journal of Clinical Medicine.2023; 12(4): 1308. CrossRef
Cancer and Mortality Risks of Graves’ Disease in South Korea Based on National Data from 2010 to 2019
Young Ju Choi, Kyungdo Han, Won Kyoung Cho, Min Ho Jung, Byung-Kyu Suh
Clinical Epidemiology.2023; Volume 15: 535. CrossRef
Risk and Prognosis of Thyroid Cancer in Patients with Graves’ Disease: An Umbrella Review
Marco Palella, Francesca Maria Giustolisi, Adriana Modica Fiascaro, Martina Fichera, Antonella Palmieri, Rossella Cannarella, Aldo E. Calogero, Margherita Ferrante, Maria Fiore
Cancers.2023; 15(10): 2724. CrossRef
Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease
Chaitra Gopinath, Hanna Crow, Sujata Panthi, Leonidas Bantis, Kenneth D. Burman, Chitra Choudhary
Journal of Clinical & Translational Endocrinology.2023; 33: 100321. CrossRef
Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
Endocrinology and Metabolism.2023; 38(4): 436. CrossRef
Hashimoto’s Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
Diagnostics.2023; 13(19): 3068. CrossRef
Table of Contents

Clinical Thyroidology.2022; 34(2): 48. CrossRef
Predisposition to and Prognosis of Thyroid Cancer May Not Be Affected by Graves’ Disease, But Some Questions Still Remain
Yanrui Huang, Haixia Guan
Clinical Thyroidology.2022; 34(2): 59. CrossRef
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves’ Disease
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Maria Rondini, Angela Spanu, Giuseppe Madeddu
Diagnostics.2022; 12(11): 2801. CrossRef
An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
Thyroid Research and Practice.2022; 19(1): 47. CrossRef

Thyroid
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea: Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim; Endocrinol Metab. 2021;36(5):1078-1085. Published online October 28, 2021; DOI: https://doi.org/10.3803/EnM.2021.1151

3,837 View
110 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.
Methods
This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.
Results
The mean age of the 97 patients included in the study was 50.3 years, and 26.8% were male. The mean size of the primary tumor was 3.2±1.8 cm, and three (3.1%) patients had distant metastasis at initial diagnosis. Ultrasonographic findings were available for 73 patients; the number of nodules with low-, intermediate-, and high suspicion was 28 (38.4%), 27 (37.0%), and 18 (24.7%), respectively, based on the Korean-Thyroid Imaging Reporting and Data System. Preoperatively, follicular neoplasm (FN) or suspicion for FN accounted for 65.2% of the cases according to the Bethesda category, and 13% had malignancy or suspicious for malignancy. During a median follow-up of 8.5 years, eight (8.2%) patients had persistent/recurrent disease, and none died of HCC. Older age, gross extrathyroidal extension (ETE), and widely invasive types of tumors were significantly associated with distant metastasis (all P<0.01). Gross ETE (hazard ratio [HR], 27.7; 95% confidence interval [CI], 2.2 to 346.4; P=0.01) and widely invasive classification (HR, 6.5; 95% CI, 1.1 to 39.4; P=0.04) were independent risk factors for poor disease-free survival (DFS).
Conclusion
The long-term prognosis of HCC is relatively favorable in South Korea from this study, although this is not a nation-wide data, and gross ETE and widely invasive cancer are significant prognostic factors for DFS. The diagnosis of HCC by ultrasonography and cytopathology remains challenging.

Citations

Citations to this article as recorded by

Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
Lindsay A. Bischoff, Ian Ganly, Laura Fugazzola, Erin Buczek, William C. Faquin, Bryan R. Haugen, Bryan McIver, Caitlin P. McMullen, Kate Newbold, Daniel J. Rocke, Marika D. Russell, Mabel Ryder, Peter M. Sadow, Eric Sherman, Maisie Shindo, David C. Shonk
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(3): 265. CrossRef
Oncocytic carcinoma of the thyroid: Conclusions from a 20‐year patient cohort
Nelson R. Gruszczynski, Shahzeb S. Hasan, Ana G. Brennan, Julian De La Chapa, Adithya S. Reddy, David N. Martin, Prem P. Batchala, Edward B. Stelow, Eric M. Dowling, Katherine L. Fedder, Jonathan C. Garneau, David C. Shonka
Head & Neck.2024;[Epub] CrossRef
Hurthle cell carcinoma: a rare variant of thyroid malignancy – a case report
Yuvraj Adhikari, Anupama Marasini, Nawaraj Adhikari, Laxman D. Paneru, Binit Upadhaya Regmi, Manita Raut
Annals of Medicine & Surgery.2023; 85(5): 1940. CrossRef
Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
Costanza Chiapponi, Milan J.M. Hartmann, Matthias Schmidt, Michael Faust, Christiane J. Bruns, Anne M. Schultheis, Hakan Alakus
Frontiers in Endocrinology.2022;[Epub] CrossRef

Thyroid
Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study: Mijin Kim, Sun Wook Cho, Young Joo Park, Hwa Young Ahn, Hee Sung Kim, Yong Joon Suh, Dughyun Choi, Bu Kyung Kim, Go Eun Yang, Il-Seok Park, Ka Hee Yi, Chan Kwon Jung, Bo Hyun Kim; Endocrinol Metab. 2021;36(3):619-627. Published online June 10, 2021; DOI: https://doi.org/10.3803/EnM.2021.974

4,633 View
178 Download
6 Web of Science
5 Crossref

Abstract PDF PubReader ePub

Background
We aimed to evaluate the clinicopathological features and biological behaviors of Korean thyroid cancer patients with rare variants of papillary thyroid carcinoma (PTC) to address the ambiguity regarding the prognostic consequences of these variants.
Methods
We retrospectively reviewed the medical records of 5,496 patients who underwent thyroid surgery for PTC, between January and December 2012, in nine tertiary hospitals. Rare PTC variants included tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail, and Warthin-like variants. Recurrence-free survival (RFS) was defined as the time from the date of thyroidectomy until recurrence.
Results
Rare variants accounted for 1.1% (n=63) of the PTC patients; with 0.9% TCV, 0.02% CCV, 0.1% DSV, 0.1% CMV, and 0.1% SV. The mean age of patients and primary tumor size were 42.1±13.1 years and 1.3±0.9 cm, respectively. Extrathyroidal extension and cervical lymph node metastasis were observed in 38 (60.3%) and 37 (58.7%) patients, respectively. Ultrasonographic findings revealed typical malignant features in most cases. During a median follow-up of 7 years, 6.3% of patients experienced a locoregional recurrence. The 5-year RFS rates were 71.4% in patients with DSV or SV, 95.9% for TCV, or CCV, and 100% for other variants. DSV emerged an independent risk factor associated with shorter RFS.
Conclusion
In this multicenter Korean cohort, rare variants accounted for 1.1% of all PTC cases, with TCV being the most frequent subtype. DSV emerged as a significant prognostic factor for RFS.

Citations

Citations to this article as recorded by

Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study
Sayid Shafi Zuhur, Hunkar Aggul, Ugur Avci, Selvinaz Erol, Mazhar Müslüm Tuna, Serhat Uysal, Gulhan Akbaba, Faruk Kilinç, Merve Catak, Sakin Tekin, Ogun Irem Bilen, Beyza Olcay Öztürk, Ecem Bilgehan Erden, Gulsah Elbuken, Halise Cinar Yavuz, Pinar Kadiogl
Hormone and Metabolic Research.2023; 55(05): 323. CrossRef
The Warthin-like variant of papillary thyroid carcinomas: a clinicopathologic analysis report of two cases
Xing Zhao, Yijia Zhang, Pengyu Hao, Mingzhen Zhao, Xingbin Shen
Oncologie.2023; 25(5): 581. CrossRef
A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes
Ayanthi Wijewardene, Anthony J. Gill, Matti Gild, Diana L. Learoyd, Anthony Robert Glover, Mark Sywak, Stan Sidhu, Paul Roach, Geoffrey Schembri, Jeremy Hoang, Bruce Robinson, Lyndal Tacon, Roderick Clifton-Bligh
Thyroid.2022;[Epub] CrossRef
Clinicopathological Implications of the BRAFV600E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident
Liudmyla Zurnadzhy, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Michael Bolgov, Serhii Chernyshov, Sergii Masiuk, Vladimir A. Saenko
Frontiers in Medicine.2022;[Epub] CrossRef

Clinical Study
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer: Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim; Endocrinol Metab. 2021;36(1):96-105. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.819

5,765 View
185 Download
14 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Several cancers show increased levels of lactate dehydrogenase A (LDHA), which are associated with cancer progression. However, it remains unclear whether LDHA levels are associated with papillary thyroid cancer (PTC) aggressiveness or with the presence of the PTC prognostic marker, the BRAFV^600E mutation. This study aimed to evaluate the potential of LDHA as a PTC prognostic marker.
Methods
LDHA expression was examined in 83 PTC tissue specimens by immunohistochemistry. Human thyroid cell lines were genetically manipulated to overexpress BRAFV^600E or were treated with a BRAF-specific short hairpin RNA (shBRAF), whose effects on LDHA expression were evaluated by Western blotting. Data from 465 PTC patients were obtained from The Cancer Genome Atlas (TCGA) database and analyzed to validate the in vitro results.
Results
LDHA was aberrantly overexpressed in PTC. Intense immunostaining for LDHA was observed in PTC specimens carrying mutated BRAF, whereas the intensity was less in wild-type BRAF samples. Overexpression of BRAFV^600E resulted in LDHA upregulation, whereas treatment with shBRAF downregulated LDHA in human thyroid cell lines. Furthermore, LDHA mRNA expression was significantly elevated and associated with BRAFV^600E expression in thyroid cancer tissues from TCGA database. Additionally, LDHA overexpression was found to be correlated with aggressive clinical features of PTC, such as lymph node metastases and advanced tumor stages.
Conclusion
LDHA overexpression is associated with the BRAFV^600E mutation and an aggressive PTC behavior. Therefore, LDHA may serve as a biomarker and therapeutic target in PTC.

Citations

Citations to this article as recorded by

Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks
Ning Qu, Di Chen, Ben Ma, Lijun Zhang, Qiuping Wang, Yuting Wang, Hongping Wang, Zhaoxian Ni, Wen Wang, Tian Liao, Jun Xiang, Yulong Wang, Shi Jin, Dixin Xue, Weili Wu, Yu Wang, Qinghai Ji, Hui He, Hai-long Piao, Rongliang Shi
Nature Communications.2024;[Epub] CrossRef
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J. Houlton, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Neal Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato G. Martins, Jonathan R. Fromm, Cristina P. Rodriguez
Cancer Medicine.2023; 12(8): 9384. CrossRef
LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer
Liang Shi, Rui Duan, Zhenhua Sun, Qiong Jia, Wenyu Wu, Feng Wang, Jianjun Liu, Hao Zhang, Xue Xue
Cell Death & Differentiation.2023; 30(6): 1517. CrossRef
Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
Guochao Ye, Xiaomei Zhang, Mansheng Li, Zixiang Lin, Yongcan Xu, Haoru Dong, Jie Zhou, Jiaqi Zhang, Sheng Wang, Yunping Zhu, Xiaobo Yu, Xu Qian
BMC Cancer.2023;[Epub] CrossRef
Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa
British Journal of Cancer.2023; 129(2): 249. CrossRef
circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
Hongguo Xie, Xiaopeng Lu
Open Medicine.2023;[Epub] CrossRef
The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
Sai-li Duan, Min Wu, Zhe-Jia Zhang, Shi Chang
Journal of Translational Medicine.2023;[Epub] CrossRef
CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma
Hui-feng Wu, Hao Liu, Zhe-wei Zhang, Ji-min Chen
European Journal of Medical Research.2023;[Epub] CrossRef
Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease
Jaime Eduardo Pachón Suárez, Marcela C. Salazar, Victor Z. Rizo
Plastic and Reconstructive Surgery - Global Open.2022; 10(2): e4137. CrossRef
Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
Endocrinology and Metabolism.2022; 37(1): 53. CrossRef
Drug delivery for metabolism targeted cancer immunotherapy
Taravat Khodaei, Sahil Inamdar, Abhirami P. Suresh, Abhinav P. Acharya
Advanced Drug Delivery Reviews.2022; 184: 114242. CrossRef
Sulfur quantum dot based fluorescence assay for lactate dehydrogenase activity detection
Shengnan Fan, Xiaoqing Li, Fanghui Ma, Minghui Yang, Juan Su, Xiang Chen
Journal of Photochemistry and Photobiology A: Chemistry.2022; 430: 113989. CrossRef
STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
Nan Huo, Rui Cong, Zhi-jia Sun, Wen-chao Li, Xiang Zhu, Chun-yuan Xue, Zhao Chen, Lu-yuan Ma, Zhong Chu, Yu-chen Han, Xiao-feng Kang, Song-hao Jia, Nan Du, Lei Kang, Xiao-jie Xu
Cell Death & Disease.2021;[Epub] CrossRef

Review Article

Thyroid
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification: Yanhua Bai, Kennichi Kakudo, Chan Kwon Jung; Endocrinol Metab. 2020;35(4):696-715. Published online December 2, 2020; DOI: https://doi.org/10.3803/EnM.2020.807

16,196 View
1,262 Download
40 Web of Science
41 Crossref

Abstract PDF PubReader ePub

Advances in medical sciences and evidence-based medicine have led to momentous changes in classification and management of thyroid neoplasms. Much progress has been made toward avoiding overdiagnosis and overtreatment of thyroid cancers. The new 2017 World Health Organization (WHO) classification of thyroid neoplasms updated the diagnostic criteria and molecular and genetic characteristics reflecting the biology and behavior of the tumors, and newly introduced the category of borderline malignancy or uncertain malignant potential. Some neoplasms were subclassified, renamed, or redefined as a specific entity. This review introduces changes in the fourth edition WHO classification of thyroid tumors and updates the contemporary diagnosis and classification of thyroid tumors. We also discuss several challenges with the proposal of new diagnostic entities, since they have unique histopathologic and molecular features and clinical relevance.

Citations

Citations to this article as recorded by

Canine thyroid carcinomas: A review with emphasis on comparing the compact subtype of follicular thyroid carcinomas and medullary thyroid carcinomas
Jillian M. Athey, Miranda D. Vieson, Keith Bailey, Dan Rudmann, Wes A. Baumgartner, Kim A. Selting
Veterinary Pathology.2024; 61(1): 7. CrossRef
Accuracy and diagnostic performance of the Bethesda system for reporting thyroid cytopathology in a tertiary endocrine surgical referral center in Belgium
Sam Kinet, Hendrik Cornette, Klaas Van Den Heede, Nele Brusselaers, Sam Van Slycke
World Journal of Surgery.2024; 48(2): 386. CrossRef
Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
Xiaoquan Hong, Juxiang Li, Shaoyin Duan, Youkuang You
PeerJ.2024; 12: e16810. CrossRef
“Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?” Observational study
Željana Matošić, Luka Šimunović, Tomislav Jukić, Roko Granić, Senka Meštrović
Progress in Orthodontics.2024;[Epub] CrossRef
Research Progress of Tg and TgAb in Lymph Node Metastasis of Papillary Thyroid Carcinoma
月高
Advances in Clinical Medicine.2024; 14(03): 499. CrossRef
A patient with a rare co‐occurrence of papillary and follicular thyroid carcinomas
Vijayvardhan Kamalumpundi, Erin Meyers, Maisoon Torfah, Marcelo Lima de Gusmão Correia
Clinical Case Reports.2024;[Epub] CrossRef
Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study
Zheng Ding, Xuanbin Tao, Xianzhao Deng, Bomin Guo, Jie Kang, Bo Wu, Zhili Yang, Chunyan Chen, Ping Liu, Yingchao Zhang, Youben Fan, Zhiyan Liu
Journal of Cancer Research and Clinical Oncology.2023; 149(9): 6303. CrossRef
Intrathyroid thymic carcinoma: clinicopathological features and whole exome sequencing analysis
Jiayu Li, Run Xiang, Yunzhu Li, Qiong Liao, Yang Liu
Virchows Archiv.2023; 482(5): 813. CrossRef
Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report
Parth S Shirode, Anil D'cruz, Sataksi Chatterjee, Swayambhu Bhandarkar
Cureus.2023;[Epub] CrossRef
Histological Variants of Papillary Thyroid Cancer in Relation to Clinical and Morphological Parameters and Prognosis
A. A. Ivanov, M. A. Bakarev, E. L. Lushnikova
Bulletin of Experimental Biology and Medicine.2023; 174(5): 647. CrossRef
Molecular profile of follicular tumors of the thyroid gland
D. D. Dolidze, A. V. Shabunin, S. D. Сovantsev, Z. A. Bagateliya, Yu. N. Kobzev, D. L. Rotin, K. A. Mulaeva, M. V. Kovaleva
Head and Neck Tumors (HNT).2023; 13(1): 102. CrossRef
The predictive models based on multimodality ultrasonography for the differential diagnosis of thyroid nodules smaller than 10 mm
Gang Li, Sai Ma, Fan Zhang, Chao Jia, Long Liu, Feng Gao, Qiusheng Shi, Rong Wu, Lianfang Du, Fan Li
The British Journal of Radiology.2023;[Epub] CrossRef
The Warthin-like variant of papillary thyroid carcinomas: a clinicopathologic analysis report of two cases
Xing Zhao, Yijia Zhang, Pengyu Hao, Mingzhen Zhao, Xingbin Shen
Oncologie.2023; 25(5): 581. CrossRef
Giant Anaplastic Thyroid Carcinoma of Sarcomatoid Type with Obstructive Symptoms: A Case Report
Gustavo D Saenz-Poma, Shirley N Cisneros-Chumacero, Juan D Millan-Landeo, Nayra Quispe-Yauri, Alba S Zevallos
World Journal of Endocrine Surgery.2023; 15(1): 18. CrossRef
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
Riet Hilhorst, Adrienne van den Berg, Piet Boender, Tom van Wezel, Tim Kievits, Rik de Wijn, Rob Ruijtenbeek, Willem E. Corver, Hans Morreau
Cancers.2023; 15(18): 4477. CrossRef
Agrin is a novel oncogenic protein in thyroid cancer
Anna Adamiok‑Ostrowska, Małgorzata Grzanka, Barbara Czarnocka
Oncology Letters.2023;[Epub] CrossRef
Investigation of pre‐operative demographic, biochemical, sonographic and cytopathological findings in low‐risk thyroid neoplasms
Muzaffer Serdar Deniz, Didem Özdemir, Narin Nasıroğlu İmga, Hüsniye Başer, Fatma Neslihan Çuhacı Seyrek, Ayşegül Aksoy Altınboğa, Oya Topaloğlu, Reyhan Ersoy, Bekir Çakır
Clinical Endocrinology.2023; 99(5): 502. CrossRef
The Asian Thyroid Working Group, from 2017 to 2023
Kennichi Kakudo, Chan Kwon Jung, Zhiyan Liu, Mitsuyoshi Hirokawa, Andrey Bychkov, Huy Gia Vuong, Somboon Keelawat, Radhika Srinivasan, Jen-Fan Hang, Chiung-Ru Lai
Journal of Pathology and Translational Medicine.2023; 57(6): 289. CrossRef
Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma
Marco De Martino, Simona Pellecchia, Myriam Decaussin-Petrucci, Domenico Testa, Nathalia Meireles Da Costa, Pierlorenzo Pallante, Paolo Chieffi, Alfredo Fusco, Francesco Esposito
Cell Cycle.2023; 22(23-24): 2552. CrossRef
RESULTS OF A MORPHOLOGICAL STUDY OF THE THYROID GLAND IN PATIENTS WITH AUTOIMMUNE THYROIDITIS
F. G. Sadikhov
World of Medicine and Biology.2023; 19(86): 137. CrossRef
Anaplastik Tiroid Karsinomu Tanısında Morfolojik ve İmmünohistokimyasal Bulguların Yeri: 10 Yıllık Seri
Özlem SARAYDAROĞLU, Rabia DÖLEK, Özen ÖZ GÜL, Ercüment GÜRLÜLER
Uludağ Üniversitesi Tıp Fakültesi Dergisi.2023; 49(3): 411. CrossRef
The Efficacy of ACR TI-RADS in the Management of Suspected Thyroid Nodules and Its Correlation With the Bethesda Scoring System
Emrah Karatay, Mirkhalig Javadov, Kinyas Kartal
Journal of Diagnostic Medical Sonography.2022; 38(4): 309. CrossRef
Systematic evaluation of the anti-tumor effect of Phellinus linteus polysaccharide in thyroid carcinoma in vitro
Kun Yu, Zhuo Tan, Ying Xin
Molecular Biology Reports.2022; 49(4): 2785. CrossRef
Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients
Xun Weng, YangYang, Yujiao Cai, Fu Wang
Disease Markers.2022; 2022: 1. CrossRef
Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
Sheng-Yao Cheng, Alexander T. H. Wu, Gaber El-Saber Batiha, Ching-Liang Ho, Jih-Chin Lee, Halimat Yusuf Lukman, Mohammed Alorabi, Abdullah N. AlRasheedi, Jia-Hong Chen
Biology.2022; 11(2): 324. CrossRef
Retrospective evaluation of radioactive iodine ablation therapy in the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) and Thyroid tumors with uncertain malignity potential
Mehmet Refik GÖKTUĞ, Özen ÖZ GÜL, Soner CANDER
Turkish Journal of Internal Medicine.2022; 4: 88. CrossRef
Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?
Małgorzata Grzanka, Anna Stachurska-Skrodzka, Anna Adamiok-Ostrowska, Ewa Gajda, Barbara Czarnocka
International Journal of Molecular Sciences.2022; 23(6): 3262. CrossRef
Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study
Tereza Grimmichova, Petra Pacesova, Martin Hill, Barbora Pekova, Marketa Vankova, Jitka Moravcova, Jana Vrbikova, Zdenek Novak, Karolina Mastnikova, Eliska Vaclavikova, Josef Vcelak, Bela Bendlova, Jana Drozenova, Vlasta Sykorova
Biomedicines.2022; 10(5): 954. CrossRef
Advantages of Small Incision Surgery in Thyroid Tumors
Wen Feng, Yuan Feng, Qixian Diao, Jian Zhou, Zhaoqi Dong
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid
Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3144. CrossRef
Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
Mohammad Hussein, Lauren Mueller, Peter P. Issa, Muhib Haidari, Lily Trinh, Eman Toraih, Emad Kandil
Biomedicines.2022; 10(8): 1984. CrossRef
Ultrasonographic characteristics of Hürthle cell neoplasms: prediction of malignancy
Min Je Kim, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh, Sun Wook Kim, Tae Hyuk Kim, Yaeji Lim, Sanghyuk Lee
Ultrasonography.2022; 41(4): 689. CrossRef
Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach
Chan Kwon Jung, Andrey Bychkov, Kennichi Kakudo
Endocrinology and Metabolism.2022; 37(5): 703. CrossRef
A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
Faridul Haq, Andrey Bychkov, Chan Kwon Jung
Endocrine Pathology.2022; 33(4): 472. CrossRef
Clinicopathological features and prognostic factors analysis of multiple synchronous distinct subtypes of primary thyroid carcinoma
Quanwei Dai, Xinghao Fu, Yalei Ding, Qi He, Xinguang Qiu
Endocrine.2022; 79(3): 491. CrossRef
Best Achievements in Clinical Thyroidology in 2020
Eun Kyung Lee, Young Joo Park
Endocrinology and Metabolism.2021; 36(1): 30. CrossRef
High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid
Ja-Seong Bae, Seung-Hyun Jung, Mitsuyoshi Hirokawa, Andrey Bychkov, Akira Miyauchi, Sohee Lee, Yeun-Jun Chung, Chan Kwon Jung
Endocrine Pathology.2021; 32(3): 336. CrossRef
Deep Learning Fast Screening Approach on Cytological Whole Slides for Thyroid Cancer Diagnosis
Yi-Jia Lin, Tai-Kuang Chao, Muhammad-Adil Khalil, Yu-Ching Lee, Ding-Zhi Hong, Jia-Jhen Wu, Ching-Wei Wang
Cancers.2021; 13(15): 3891. CrossRef
How to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery—Risk stratification of papillary thyroid carcinoma in young patients—
Kennichi Kakudo, Zhiyan Liu, Yanhua Bai, Yaqiong Li, Naomi Kitayama, Shinya Satoh, Masahiro Nakashima, Chan Kwon Jung
Endocrine Journal.2021; 68(8): 871. CrossRef
Papillary Thyroid Cancer Prognosis: An Evolving Field
Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvator
Cancers.2021; 13(21): 5567. CrossRef
Intrasalivary Thymic Carcinoma: A Case Report and Literature Review
Michał Kunc, Alexandra Kamieniecki, Grzegorz Walczak, Tomasz Nowicki, Bartosz Wasąg, Bogusław Mikaszewski, Dominik Stodulski, Wojciech Biernat
Head and Neck Pathology.2021; 16(3): 857. CrossRef

Original Articles

Clinical Study
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis: Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim; Endocrinol Metab. 2020;35(4):830-837. Published online November 18, 2020; DOI: https://doi.org/10.3803/EnM.2020.747

4,203 View
131 Download
3 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC.
Methods
We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM).
Results
Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM.
Conclusion
The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

Citations

Citations to this article as recorded by

Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich
Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef
Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
Kathryn Graham, Fay Tough, Helena Belikova, Irene Wotherspoon, David Colville, Nicholas Reed
Endocrine Practice.2024; 30(4): 327. CrossRef
Radioiodine ablation after thyroidectomy could be safely abandoned or postponed in selected stage I papillary thyroid carcinoma patients of low-risk group: an observational prospective study
S.M. Cherenko, A.Yu. Glagolieva, D.E. Makhmudov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(1): 7. CrossRef
Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
Clinical Oncology.2023; 35(1): 42. CrossRef
Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
Fang Cheng, Juan Xiao, Fengyan Huang, Chunchun Shao, Shouluan Ding, Canhua Yun, Hongying Jia
Cancer Medicine.2022; 11(12): 2386. CrossRef
Delayed (>3 Months) Postoperative Radioactive Iodine Ablation Does Not Impact Clinical Response or Survival in Differentiated Thyroid Cancers
Tatiana Fedorova, Lilah F. Morris-Wiseman
Clinical Thyroidology.2022; 34(10): 456. CrossRef

Endocrine Research
Liver X Receptor β Related to Tumor Progression and Ribosome Gene Expression in Papillary Thyroid Cancer: Seonhyang Jeong, In-Kyu Kim, Hyunji Kim, Moon Jung Choi, Jandee Lee, Young Suk Jo; Endocrinol Metab. 2020;35(3):656-668. Published online August 20, 2020; DOI: https://doi.org/10.3803/EnM.2020.667

6,544 View
131 Download
8 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Intracellular lipid deposition has been reported in thyroid glands in obese animal and human. To understand the regulatory mechanism of lipid metabolism in thyroid cancer, we investigated the expression status of liver X receptor (LXR) and analyzed its clinicopathological characteristics and molecular biological features.
Methods
Expression status of LXR and its transcriptional targets in human cancers were analyzed using The Cancer Genome Atlas (TCGA). The gene-sets related to high LXRβ expression was investigated by gene set enrichment analysis (GSEA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways and gene ontology biologic process. Quantitative reverse transcription polymerase chain reaction was performed in thyroid cancer samples using our validation cohort.
Results
In contrast to low expression of LXRα, LXRβ was highly expressed in thyroid cancer compared to the other types of human cancers. High LXRβ expression was correlated with the expression of LXRβ transcriptional targets genes, such as apolipoprotein C1 (APOC1), APOC2, apolipoprotein E (APOE), ATP binding cassette subfamily G member 8 (ABCG8), sterol regulatory elementbinding protein 1c (SREBP1c), and SPOT14. Furthermore, High LXRβ expression group indicated poor clinicopathological characteristics and aggressive molecular biological features independently from the drive mutation status. Mechanistically, high LXRβ expression was coordinately related to ribosome-related gene sets.
Conclusion
The mechanistic link between LXRβ and ribosomal activity will be addressed to develop new diagnostic and therapeutic targets in thyroid cancers.

Citations

Citations to this article as recorded by

ApoC1 promotes glioma metastasis by enhancing epithelial-mesenchymal transition and activating the STAT3 pathway
Rui Liang, Guofeng Zhang, Wenhua Xu, Weibing Liu, Youjia Tang
Neurological Research.2023; 45(3): 268. CrossRef
The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice
Lyndsey A. Reich, Ana S. Leal, Edmund Ellsworth, Karen T. Liby
International Journal of Molecular Sciences.2023; 24(5): 4298. CrossRef
The Role of Apolipoproteins in the Commonest Cancers: A Review
Nour M. Darwish, Mooza Kh. Al-Hail, Youssef Mohamed, Rafif Al Saady, Sara Mohsen, Amna Zar, Layla Al-Mansoori, Shona Pedersen
Cancers.2023; 15(23): 5565. CrossRef
Apolipoproteins: New players in cancers
Yingcheng He, Jianrui Chen, Yanbing Ma, Hongping Chen
Frontiers in Pharmacology.2022;[Epub] CrossRef
Simultaneous Expression of Long Non-Coding RNA FAL1 and Extracellular Matrix Protein 1 Defines Tumour Behaviour in Young Patients with Papillary Thyroid Cancer
Seonhyang Jeong, Seul-Gi Lee, Hyunji Kim, Gibbeum Lee, Sunmi Park, In-Kyu Kim, Jandee Lee, Young-Suk Jo
Cancers.2021; 13(13): 3223. CrossRef
Using BioPAX-Parser (BiP) to enrich lists of genes or proteins with pathway data
Giuseppe Agapito, Mario Cannataro
BMC Bioinformatics.2021;[Epub] CrossRef
Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer
Mian Liu, Rooh Afza Khushbu, Pei Chen, Hui-Yu Hu, Neng Tang, Deng-jie Ou-yang, Bo Wei, Ya-xin Zhao, Peng Huang, Shi Chang
Frontiers in Oncology.2021;[Epub] CrossRef
Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment
Lisha Bao, Tong Xu, Xixuan Lu, Ping Huang, Zongfu Pan, Minghua Ge
Frontiers in Oncology.2021;[Epub] CrossRef
Cooperative Subtype Switch of Thyroid Hormone Receptor and Nuclear Receptor Corepressor Related Epithelial–Mesenchymal Transition in Papillary Thyroid Cancer
Seonhyang Jeong, Seul Gi Lee, Hyunji Kim, Gibbeum Lee, Sunmi Park, In-Kyu Kim, Jandee Lee, Young Suk Jo
International Journal of Thyroidology.2021; 14(2): 152. CrossRef

Clinical Study
Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer: Sunghwan Suh, Tae Sik Goh, Yun Hak Kim, Sae-Ock Oh, Kyoungjune Pak, Ju Won Seok, In Joo Kim; Endocrinol Metab. 2020;35(2):435-442. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.435; Correction in: Endocrinol Metab 2023;38(2):287

5,511 View
130 Download
3 Web of Science
2 Crossref

Abstract PDF PubReader ePub

Background
The aim of this study was to develop a scoring system to stratify the risk of papillary thyroid cancer (PTC) and to select the proper management.
Methods
We performed a systematic search of MEDLINE and Embase. Data regarding patients’ prognoses were obtained from the included studies. Odds ratios (ORs) with statistical significance were extracted from the publications. To generate a risk scoring system (RSS), ORs were summed (RSS1), and summed after natural-logarithmic transformation (RSS2). RSS1 and RSS2 were compared to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system and the 2015 American Thyroid Association (ATA) guidelines for thyroid nodules and differentiated thyroid carcinoma.
Results
Five meta-analyses were eligible for inclusion in the study. Eight variables (sex, tumour size, extrathyroidal extension, BRAF mutation, TERT mutation, histologic subtype, lymph node metastasis, and distant metastasis) were included. RSS1 was the best of the analysed models.
Conclusion
We developed and validated a new RSS derived from previous meta-analyses for patients with PTC. This RSS seems to be superior to previously published systems.

Citations

Citations to this article as recorded by

Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review
Hongxi Wang, Hongyuan Dai, Qianrui Li, Guohua Shen, Lei Shi, Rong Tian
Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
Joohyun Woo, Hyeonkyeong Kim, Hyungju Kwon
Journal of Clinical Medicine.2021; 10(21): 5144. CrossRef

Clinical Study
Subclinical Hypothyroidism Affects the Long-Term Outcomes of Patients Who Undergo Coronary Artery Bypass Grafting Surgery but Not Heart Valve Surgery: Hana Kim, Sung Hye Kong, Jae Hoon Moon, Sang Yoon Kim, Kay-Hyun Park, Jun Sung Kim, Joong Haeng Choh, Young Joo Park, Cheong Lim; Endocrinol Metab. 2020;35(2):308-318. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.308

6,463 View
151 Download
9 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The aim of this study was to determine the associations between subclinical hypothyroidism (SCH) and long-term cardiovascular outcomes after coronary artery bypass grafting (CABG) or heart valve surgery (HVS).
Methods
We retrospectively reviewed and compared all-cause mortality, cardiovascular mortality, and cardiovascular events in 461 patients who underwent CABG and 104 patients who underwent HVS.
Results
During a mean±standard deviation follow-up duration of 7.6±3.8 years, there were 187 all-cause deaths, 97 cardiovascular deaths, 127 major adverse cardiovascular events (MACE), 11 myocardial infarctions, one unstable angina, 70 strokes, 30 hospitalizations due to heart failure, 101 atrial fibrillation, and 33 coronary revascularizations. The incidence of all-cause mortality after CABG was significantly higher in patients with SCH (n=36, 55.4%) than in euthyroid patients (n=120, 30.3%), with a hazard ratio of 1.70 (95% confidence interval, 1.10 to 2.63; P=0.018) after adjustment for age, sex, current smoking status, body mass index, underlying diseases, left ventricular dysfunction, and emergency operation. Interestingly, low total triiodothyronine (T3) levels in euthyroid patients who underwent CABG were significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and MACE, but those associations were not observed in HVS patients. Both free thyroxine and thyroid-stimulating hormone levels in euthyroid patients were not related with any cardiovascular outcomes in either the CABG or HVS group.
Conclusion
SCH or low total T3 might be associated with a poor prognosis after CABG, but not after HVS, implying that preoperative thyroid hormonal status may be important in ischemic heart disease patients.

Citations

Citations to this article as recorded by

Subclinical hypothyroidism and clinical outcomes after cardiac surgery: A systematic review and meta-analysis
Michele Dell’Aquila, Camilla S. Rossi, Tulio Caldonazo, Gianmarco Cancelli, Lamia Harik, Giovanni J. Soletti, Kevin R. An, Jordan Leith, Hristo Kirov, Mudathir Ibrahim, Michelle Demetres, Arnaldo Dimagli, Mohamed Rahouma, Mario Gaudino
JTCVS Open.2024; 18: 64. CrossRef
The Association Between Hypothyroidism Treatment and Mortality in Patients Hospitalized in Surgical Wards
Hiba Masri-Iraqi, Yaron Rudman, Carmel Friedrich Dubinchik, Idit Dotan, Talia Diker-Cohen, Liat Sasson, Tzipora Shochat, Ilan Shimon, Eyal Robenshtok, Amit Akirov
Endocrine Research.2023; 48(2-3): 68. CrossRef
Mid-term outcomes of patients with subclinical hypothyroidism after coronary bypass surgery
Dong Zhao, Wei Zhao, Chuangshi Wang, Fei Xu, Wei Zhao, Xieraili Tiemuerniyazi, Hao Ma, Wei Feng
Interdisciplinary CardioVascular and Thoracic Surgery.2023;[Epub] CrossRef
Thyroid Pathology in High-Risk Cardiac Surgery Patients with Coronary Artery Disease
Olena K. Gogayeva, Anatoliy V. Rudenko, Vasyl V. Lazoryshynets, Serhii A. Rudenko, Tetiana A. Andrushchenko
Ukrainian Journal of Cardiovascular Surgery.2022; 30(1 (46)): 9. CrossRef
High-TSH Subclinical Hypothyroidism Is Associated With Postoperative Mortality in Acute Type A Aortic Dissection
Shi-Pan Wang, Yuan Xue, Hai-Yang Li, Wen-Jian Jiang, Hong-Jia Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Triiodothyronine improves contractile recovery of human atrial trabeculae after hypoxia/reoxygenation
Petra Kleinbongard, Philipp Kuthan, Chantal Eickelmann, Philipp Jakobs, Joachim Altschmied, Judith Haendeler, Arjang Ruhparwar, Matthias Thielmann, Gerd Heusch
International Journal of Cardiology.2022; 363: 159. CrossRef
Hypothyroidism Is Correlated with Ventilator Complications and Longer Hospital Days after Coronary Artery Bypass Grafting Surgery in a Relatively Young Population: A Nationwide, Population-Based Study
Jiun-Yu Lin, Pei-Chi Kao, Yi-Ting Tsai, Chi-Hsiang Chung, Wu-Chien Chien, Chih-Yuan Lin, Chieh-Hua Lu, Chien-Sung Tsai
Journal of Clinical Medicine.2022; 11(13): 3881. CrossRef
Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence
Patrick Müller, Melvin Khee-Shing Leow, Johannes W. Dietrich
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
Won Sang Yoo, Hyun Kyung Chung
Endocrinology and Metabolism.2021; 36(3): 500. CrossRef

Clinical Study
Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service: Jung Hee Kim, Hyemi Moon, Junghyun Noh, Juneyoung Lee, Sin Gon Kim; Endocrinol Metab. 2020;35(1):157-164. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.157

7,239 View
172 Download
26 Web of Science
24 Crossref

Abstract PDF PubReader ePub

Background

Pheochromocytomas and paragangliomas (PPGLs) are rare endocrine tumors originating from chromaffin cells. PPGLs are associated with a high mortality rate and several complications. To date, no epidemiological studies have been conducted on PPGLs in Asia. This study aimed to investigate the epidemiology and prognosis of PPGLs in Korea using nationwide data.

Methods

Using the National Health Insurance Service Database, subjects with a principal diagnosis of PPGLs on two or more occasions between 2003 and 2014 who satisfied the operational definition of PPGLs were included. Incidence, prevalence, complications, metastasis, and mortality were investigated.

Results

In total, 1048 subjects with a mean age of 47.6±16.1 years were included. There was no sex preponderance. The overall prevalence of PPGLs was 2.13 per 100,000 persons, and the overall age-standardized incidence rate was 0.18 per 100,000 person-years. Malignant PPGLs accounted for 17.7% (185 of 1,048) of cases, and 94 subjects exhibited metastasis at the time of diagnosis. Among initially non-metastatic PPGLs, 9.5% (nine of 954) eventually metastasized after a mean duration of 78.1±41.4 months. The 5-year survival rates for non-metastatic and metastatic PPGLs at diagnosis were 97% and 84%, respectively. Multivariable Cox regression models adjusted for covariates showed that metastatic PPGLs were associated with a 2.40-fold higher risk of mortality than non-metastatic PPGLs (95% confidence interval, 1.38 to 4.17; P=0.002).

Conclusion

PPGLs are rare in Korea, and the prognosis of these endocrine tumors varies depending on whether they are benign or malignant. This epidemiological study paves the way for further research on PPGLs.

Citations

Citations to this article as recorded by

Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician
Sona Sharma, Lauren Fishbein
Endocrine Practice.2023; 29(12): 999. CrossRef
Pheochromocytoma: a changing perspective and current concepts
Andreas Kiriakopoulos, Periklis Giannakis, Evangelos Menenakos
Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub] CrossRef
Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas
Gildas Gabiache, Charline Zadro, Laura Rozenblum, Delphine Vezzosi, Céline Mouly, Matthieu Thoulouzan, Rosine Guimbaud, Philippe Otal, Lawrence Dierickx, Hervé Rousseau, Christopher Trepanier, Laurent Dercle, Fatima-Zohra Mokrane
Cancers.2023; 15(18): 4666. CrossRef
Trends in the incidence of adrenocortical carcinoma and pheochromocytoma/paraganglioma in Taiwan
Chung-Hsin Tsai, Tun-Sung Huang, Shih-Ping Cheng
Formosan Journal of Surgery.2023; 56(5): 147. CrossRef
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
Anri Inaki, Tohru Shiga, Yoshito Tsushima, Megumi Jinguji, Hiroshi Wakabayashi, Daiki Kayano, Norihito Akatani, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Tomo Hiromasa, Hiroshi Mori, Kenji Hirata, Shiro Watanabe, Tetsuya Higuchi, Hiroyasu Tomonaga, S
Annals of Nuclear Medicine.2022; 36(3): 267. CrossRef
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
Jan Calissendorff, Carl Christofer Juhlin, Irina Bancos, Henrik Falhammar
Cancers.2022; 14(4): 917. CrossRef
Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Kyu Eun Lee, Kyeong Cheon Jung
Frontiers in Endocrinology.2022;[Epub] CrossRef
Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Cancers.2022; 14(8): 1967. CrossRef
Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years
Abdul Rahman Al Subhi, Veronica Boyle, Marianne S Elston
Journal of the Endocrine Society.2022;[Epub] CrossRef
Incidence and risk factors for myocardial injury after laparoscopic adrenalectomy for pheochromocytoma: A retrospective cohort study
Ling Lan, Qian Shu, Chunhua Yu, Lijian Pei, Yuelun Zhang, Li Xu, Yuguang Huang
Frontiers in Oncology.2022;[Epub] CrossRef
The Clinical Characteristics of Pheochromocytomas and Paragangliomas with Negative Catecholamines
Lin Zhao, Xiaoran Zhang, Xu Meng, Ting Zhang, Hua Fan, Qiongyu Zhang, Yecheng Liu, Xianliang Zhou, Huadong Zhu
Journal of Clinical Medicine.2022; 11(19): 5583. CrossRef
A midline ectopic paraganglioma
Christina SANT FOURNIER, Matthias FARRUGIA, Kimberley PACE, Christian CAMENZULI, Alexander R. ATTARD
Chirurgia.2022;[Epub] CrossRef
Non-Selective Alpha-Blockers Provide More Stable Intraoperative Hemodynamic Control Compared with Selective Alpha1-Blockers in Patients with Pheochromocytoma and Paraganglioma: A Single-Center Retrospective Cohort Study with a Propensity Score-Matched Ana
Yang Yang, Jie Zhang, Liqun Fang, Xue Jia, Wensheng Zhang
Drug Design, Development and Therapy.2022; Volume 16: 3599. CrossRef
Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study
Andreas Ebbehoj, Kirstine Stochholm, Sarah Forslund Jacobsen, Christian Trolle, Peter Jepsen, Maciej Grzegorz Robaczyk, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Reimar Wernich Thomsen, Esben Søndergaard, Per Løgstrup Poulsen
The Journal of Clinical Endocrinology & Metabolism.2021; 106(5): e2251. CrossRef
Determinants of anxiety and depression among pheochromocytoma patients
Siming Jia, Chengbai Li, Zhuqing Lei, Qiang Xia, Yuqing Jiang
Medicine.2021; 100(3): e24335. CrossRef
Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases
Akiyuki Kawashima, Masakatsu Sone, Nobuya Inagaki, Kentaro Okamoto, Mika Tsuiki, Shoichiro Izawa, Michio Otsuki, Shintaro Okamura, Takamasa Ichijo, Takuyuki Katabami, Yoshiyu Takeda, Takanobu Yoshimoto, Mitsuhide Naruse, Akiyo Tanabe
Endocrine.2021; 74(1): 155. CrossRef
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
Endocrinology and Metabolism.2021; 36(2): 322. CrossRef
Clinical Presentation and Perioperative Management of Pheochromocytomas and Paragangliomas: A 4-Decade Experience
Thomas Uslar, Ignacio F San Francisco, Roberto Olmos, Stefano Macchiavelo, Alvaro Zuñiga, Pablo Rojas, Marcelo Garrido, Alvaro Huete, Gonzalo P Mendez, Ignacio Cortinez, José Tomás Zemelman, Joaquín Cifuentes, Fernando Castro, Daniela Olivari, José Miguel
Journal of the Endocrine Society.2021;[Epub] CrossRef
Pheochromocytoma
Zhonghua Liu, Junsheng Ma, Camilo Jimenez, Miao Zhang
American Journal of Surgical Pathology.2021; 45(9): 1155. CrossRef
Perioperative hemodynamic instability in pheochromocytoma and sympathetic paraganglioma patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Soo Bin Yoon, Sung Hye Kong, Hyeong Won Yu, Young Jun Chai, June Young Choi, Kyu Eun Lee, Kwang-Woong Lee, Seung-Kee Min, Chan Soo Shin, Kyu Joo Park
Scientific Reports.2021;[Epub] CrossRef
Changes in the Nociception Level Index During Surgical Resection of Paragangliomas: A Case Report
Rita Saynhalath, Umar H. Khan, Gijo Alex, Joseph T. Murphy, Peter Szmuk
A&A Practice.2021; 15(11): e01542. CrossRef
Hypertension Cure and Reducing Pill Burden after Adrenalectomy for Endocrine Hypertension of Adrenal Origin: A Comparative Study from an Asian and UK Cohort
Kee Y Ngiam, Ciaran Durand, Titus C Vasciuc, Chia H Tai, Raluca Orpean, Fiona Eatock, Mehak Mahipal, Tan W Boon
World Journal of Endocrine Surgery.2021; 13(1): 9. CrossRef
A Brief Overview of the Epidemiology of Pheochromocytoma and Paraganglioma in Korea
Yun Mi Choi
Endocrinology and Metabolism.2020; 35(1): 95. CrossRef

Review Article

Thyroid
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer: Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong; Endocrinol Metab. 2020;35(1):14-25. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.14

6,999 View
132 Download
14 Web of Science
10 Crossref

Abstract PDF PubReader ePub

The increased incidence of thyroid cancer is a worldwide phenomenon; however, the issue of overdiagnosis has been most prominent in South Korea. The age-standardized mortality rate of thyroid cancer in Korea steeply increased from 1985 to 2004 (from 0.17 per 100,000 to 0.85 per 100,000), and then decreased until 2015 to 0.42 per 100,000, suggesting that early detection reduced mortality. However, early detection of thyroid cancer may be cost-ineffective, considering its very high prevalence and indolent course. Therefore, risk stratification and tailored management are vitally important, but many prognostic markers can only be evaluated postoperatively. Discovery of preoperative marker(s), especially for small cancers, is the most important unmet clinical need for thyroid cancer. Herein, we discuss some such factors that we recently discovered. Another unmet clinical need is better treatment of radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) and undifferentiated cancers. Although sorafenib and lenvatinib are available, better drugs are needed. We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.

Citations

Citations to this article as recorded by

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
Thyroid.2023; 33(1): 91. CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Integration of ultrasound-based radiomics with clinical features for predicting cervical lymph node metastasis in postoperative patients with differentiated thyroid carcinoma
Fengjing Fan, Fei Li, Yixuan Wang, Zhengjun Dai, Yuyang Lin, Lin Liao, Bei Wang, Hongjun Sun
Endocrine.2023;[Epub] CrossRef
Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo
Clinical and Experimental Otorhinolaryngology.2022; 15(2): 183. CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef
Carboxy terminus of HSP70‐interacting protein (CHIP) attenuates the stemness of thyroid cancer cells through decreasing OCT4 protein stability
Ying Xu, Gang Xu, Huimin Dang, Wei Qu, Dan Chang, Xin He, Minmin Li, Qian Wang
Environmental Toxicology.2021; 36(4): 686. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
Clinical Endocrinology.2021; 95(6): 882. CrossRef
CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov, Chan Kwon Jung
Cancers.2020; 12(10): 3042. CrossRef
The Role of Exosomes in Thyroid Cancer and Their Potential Clinical Application
Kaixiang Feng, Runsheng Ma, Lele Zhang, Hongqiang Li, Yifeng Tang, Gongbo Du, Dongpeng Niu, Detao Yin
Frontiers in Oncology.2020;[Epub] CrossRef

Original Articles

Clinical Study
Protein Expression of Cyclin B1, Transferrin Receptor, and Fibronectin Is Correlated with the Prognosis of Adrenal Cortical Carcinoma: Sun Joon Moon, Jung Hee Kim, Sung Hye Kong, Chan Soo Shin; Endocrinol Metab. 2020;35(1):132-141. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.132

10,646 View
91 Download
10 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Adrenal cortical carcinoma (ACC) is a rare cancer with a variable prognosis. Several prognostic factors of ACC have been previously reported, but a proteomic analysis has not yet been performed. This study aimed to investigate prognostic biomarkers for ACC using a proteomic approach.

Methods

We used reverse-phase protein array data from The Cancer Proteome Atlas, and identified differentially expressed proteins in metastatic ACCs. Multivariate Cox regression analysis adjusted by age and staging was used for survival analysis, and the C-index and category-free net reclassification improvement (cfNRI) were utilized to evaluate additive prognostic value.

Results

In 46 patients with ACC, cyclin B1, transferrin receptor (TfR1), and fibronectin were significantly overexpressed in patients with distant metastasis. In multivariate models, high expression of cyclin B1 and TfR1 was significantly associated with mortality (hazard ratio [HR], 6.13; 95% confidence interval [CI], 1.02 to 36.7; and HR, 6.59; 95% CI, 1.14 to 38.2; respectively), whereas high fibronectin expression was not (HR, 3.92; 95% CI, 0.75 to 20.4). Combinations of high cyclin B1/high TfR1, high cyclin B1/high fibronectin, and high TfR1/high fibronectin were strongly associated with mortality ([HR, 13.72; 95% CI, 1.89 to 99.66], [HR, 9.22; 95% CI, 1.34 to 63.55], and [HR, 18.59; 95% CI, 2.54 to 135.88], respectively). In reclassification analyses, cyclin B1, TfR1, fibronectin, and combinations thereof improved the prognostic performance (C-index, 0.78 to 0.82–0.86; cfNRI, all P values <0.05).

Conclusion

In ACC patients, the overexpression of cyclin B1, TfR1, and fibronectin and combinations thereof were associated with poor prognosis.

Citations

Citations to this article as recorded by

USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression
Yue Xiao, Xinyi Chen, Weiwei Hu, Wenjing Ma, Qianqian Di, Haimei Tang, Xibao Zhao, Guodong Huang, Weilin Chen
Translational Oncology.2023; 34: 101713. CrossRef
Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis
Mengsha Yin, Yao Wang, Xinhua Ren, Mingyue Han, Shanshan Li, Ruishuang Liang, Guixia Wang, Xiaokun Gang
Frontiers in Endocrinology.2023;[Epub] CrossRef
Identification of Key Genes and Related Drugs of Adrenocortical Carcinoma by Integrated Bioinformatics Analysis
Jian-bin Wei, Xiao-chun Zeng, Kui-rong Ji, Ling-yi Zhang, Xiao-min Chen
Hormone and Metabolic Research.2023;[Epub] CrossRef
Ferritin nanocage based delivery vehicles: From single-, co- to compartmentalized- encapsulation of bioactive or nutraceutical compounds
Hai Chen, Xiaoyi Tan, Xueer Han, Liang Ma, Hongjie Dai, Yu Fu, Yuhao Zhang
Biotechnology Advances.2022; 61: 108037. CrossRef
Effect of Inactivation of Mst1 and Mst2 in the Mouse Adrenal Cortex
Nour Abou Nader, Étienne Blais, Guillaume St-Jean, Derek Boerboom, Gustavo Zamberlam, Alexandre Boyer
Journal of the Endocrine Society.2022;[Epub] CrossRef
Cyclin B1 expression as an independent prognostic factor for lung adenocarcinoma and its potential pathways
Yi Li, Yuanxiu Leng, Yudi Dong, Yongxiang Song, Qiaoyuan Wu, Ni Jiang, Hui Dong, Fang Chen, Qing Luo, Chen Cheng
Oncology Letters.2022;[Epub] CrossRef
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Pierre V. Candelaria, Lai Sum Leoh, Manuel L. Penichet, Tracy R. Daniels-Wells
Frontiers in Immunology.2021;[Epub] CrossRef
Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma
Han Na Jang, Sun Joon Moon, Kyeong Cheon Jung, Sang Wan Kim, Hyeyoon Kim, Dohyun Han, Jung Hee Kim
Cancers.2021; 13(15): 3890. CrossRef
Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer
Milad Ashrafizadeh, Kiavash Hushmandi, Ebrahim Rahmani Moghadam, Vahideh Zarrin, Sharareh Hosseinzadeh Kashani, Saied Bokaie, Masoud Najafi, Shima Tavakol, Reza Mohammadinejad, Noushin Nabavi, Chia-Ling Hsieh, Atefeh Zarepour, Ehsan Nazarzadeh Zare, Ali Z
Bioengineering.2020; 7(3): 91. CrossRef

Thyroid
Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies: Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Young Joo Park; Endocrinol Metab. 2018;33(4):473-484. Published online November 30, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.4.473

8,061 View
114 Download
57 Web of Science
55 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Epidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.

Methods

We searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins I² statistic was used to test for heterogeneity.

Results

The meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61).

Conclusion

In this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.

Citations

Citations to this article as recorded by

Malignancy risk of indeterminate lymph node at the central compartment in patients with thyroid cancer and concomitant sonographic thyroiditis
Jung Hyo Rhim, Ji Ye Lee, Sun‐Won Park, Younghen Lee, So Lyung Jung, Tae Jin Yun, Eun Ju Ha, Jung Hwan Baek, Jinna Kim, Dong Gyu Na, Ji‐hoon Kim
Head & Neck.2024;[Epub] CrossRef
Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, Shinje Moon
Endocrinology and Metabolism.2024;[Epub] CrossRef
Interaction of BANCR in the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma expression patterns and possible molecular mechanisms
Jiabo Zhang, Lingli Yao, Yu Guo
The Journal of Gene Medicine.2024;[Epub] CrossRef
Association between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis
Jie Liu
Clinical Thyroidology®.2024; 36(1): 26. CrossRef
Risk prediction for central lymph node metastasis in isolated isthmic papillary thyroid carcinoma by nomogram: A retrospective study from 2010 to 2021
Yu Zhao, Wei Shi, Fang Dong, Xiuhua Wang, Chong Lu, Chunping Liu
Frontiers in Endocrinology.2023;[Epub] CrossRef
The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study
Shirzad Nasiri, Seyed Mostafa Meshkati Yazd, Mahsa Gholami, Sepehr Shahriarirad, Sina Sharghi, Reza Shahriarirad
BMC Endocrine Disorders.2023;[Epub] CrossRef
Hashimoto’s Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma
Peter P. Issa, Mahmoud Omar, Yusef Buti, Mohamed Aboueisha, Ruhul Munshi, Mohammad Hussein, Muhib Haidari, Graham Blair, Chad P. Issa, Mohamed Shama, Eman Toraih, Emad Kandil
Cancers.2023; 15(8): 2371. CrossRef
VITAMIN D AND AUTOIMMUNE THYROIDITIS
K. V. Pivtorak, O. V Ivanhuk O. V
Bulletin of Problems Biology and Medicine.2023; 1(1): 44. CrossRef
Does the Association of Hashimoto's Thyroiditis with Differentiated Thyroid Cancer Really Have a Protective Role?
Ahmet Numan Demir, Zehra Kara, Cem Sulu, Serhat Uysal, Serdar Sahin, Guldana Zulfaliyeva, Oznur Aydin Atar, Nahida Valikhanova, Tulin Ozturk, Hande Mefkure Ozkaya, Mustafa Sait Gonen
Hormone and Metabolic Research.2023; 55(06): 388. CrossRef
Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000-2022
Dominika Januś, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Monika Kujdowicz, Małgorzata Czogała, Wojciech Górecki, Jerzy B. Starzyk
Frontiers in Endocrinology.2023;[Epub] CrossRef
Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
Havva Sezer, Dilek Yazıcı, Tarık Terzioğlu, Serdar Tezelman, Hande Bulut Canbaz, Aslıhan Yerlikaya, Mehmet Onur Demirkol, Yersu Kapran, Bülent Çolakoğlu, Eda Nur Çilingiroğlu, Faruk Alagöl
The American Surgeon™.2023; 89(12): 5996. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Clonal redemption of B cells in cancer
Tyler R. McCaw, Serena Y. Lofftus, Joseph G. Crompton
Frontiers in Immunology.2023;[Epub] CrossRef
Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto’s thyroiditis: a systematic review with meta-analysis
Lukasz Janicki, Agastya Patel, Jarosław Jendrzejewski, Andrzej Hellmann
Frontiers in Endocrinology.2023;[Epub] CrossRef
The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
Nese E. GULCELIK, Safak AKIN, Kadriye AYDIN, Cisel AYDIN MERICOZ, Yesim G. GULER TEZEL, Aydan USMAN
Minerva Endocrinology.2023;[Epub] CrossRef
Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer
Richard M. Yeker, Amber D. Shaffer, Pushpa Viswanathan, Selma F. Witchel, Kevin Mollen, Linwah Yip, Sara E. Monaco, Umamaheswar Duvvuri, Jeffrey P. Simons
The Laryngoscope.2022; 132(8): 1668. CrossRef
Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling
Xuan Zhang, Nan Guo, Hao Jin, Renqi Liu, Zhen Zhang, Cheng Cheng, Zhijun Fan, Guopei Zhang, Mingyang Xiao, Shengwen Wu, Yuejiao Zhao, Xiaobo Lu
Journal of Hazardous Materials.2022; 425: 127911. CrossRef
Squamous Differentiation in the Thyroid: Metaplasia, Neoplasia, or Bystander?
Meagan A. Chambers, Peter M. Sadow, Darcy A. Kerr
International Journal of Surgical Pathology.2022; 30(4): 385. CrossRef
Vitamin D Implications and Effect of Supplementation in Endocrine Disorders: Autoimmune Thyroid Disorders (Hashimoto’s Disease and Grave’s Disease), Diabetes Mellitus and Obesity
Dorina Galușca, Mihaela Simona Popoviciu, Emilia Elena Babeș, Mădălina Vidican, Andreea Atena Zaha, Vlad Victor Babeș, Alexandru Daniel Jurca, Dana Carmen Zaha, Florian Bodog
Medicina.2022; 58(2): 194. CrossRef
Central Compartment Lymph Nodes Have Distinct Metastatic Patterns in Different Age Groups
Caigu Yan, Xianghui He, Zuoyu Chen, Yizeng Wang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Synchronous occurrence of papillary thyroid microcarcinoma, medullary thyroid carcinoma and Hashimoto thyroiditis in a single thyroid: A case report with literature review
Ari M. Abdullah, Rawa M. Ali, Karzan M. Salih, Karukh K. Mohammed, Fahmi H. Kakamad, Abdulwahid M. Salih
International Journal of Surgery Case Reports.2022; 93: 106888. CrossRef
Benign and malignant thyroid nodules with autoimmune thyroiditis
Georgia N. Kassi, Catherine C. Evangelopoulou, Konstantinos D. Papapostolou, Helen J. Karga
Archives of Endocrinology and Metabolism.2022;[Epub] CrossRef
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
PLOS ONE.2022; 17(6): e0269995. CrossRef
A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess
David D. Dolidze, Alexey V. Shabunin, Robert B. Mumladze, Arshak V. Vardanyan, Serghei D. Covantsev, Alexander M. Shulutko, Vasiliy I. Semikov, Khalid M. Isaev, Airazat M. Kazaryan
Frontiers in Oncology.2022;[Epub] CrossRef
Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers
Natália Medeiros Dias Lopes, Hannah Hamada Mendonça Lens, Walison Augusto da Silva Brito, Julya Karen Bianchi, Poliana Camila Marinello, Rubens Cecchini, André Armani, Alessandra Lourenço Cecchini
Clinical and Translational Oncology.2022; 24(12): 2366. CrossRef
Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: A bibliometric analysis
Qiuxian Li, Wanyu Yang, Jiashu Li, Zhongyan Shan
Frontiers in Immunology.2022;[Epub] CrossRef
The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis
Fabiana Pani, Paola Caria, Yoshinori Yasuda, Miyara Makoto, Stefano Mariotti, Laurence Leenhardt, Solmaz Roshanmehr, Patrizio Caturegli, Camille Buffet
Cancers.2022; 14(17): 4287. CrossRef
Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
Yuepeng Zhang, Yueli Tian
BMC Endocrine Disorders.2022;[Epub] CrossRef
Elastographic Evaluation of Thyroid Nodules in Children and Adolescents with Hashimoto’s Thyroiditis and Nodular Goiter with Reference to Cytological and/or Histopathological Diagnosis
Hanna Borysewicz-Sańczyk, Beata Sawicka, Filip Bossowski, Janusz Dzięcioł, Artur Bossowski
Journal of Clinical Medicine.2022; 11(21): 6339. CrossRef
Prognostic value of the preoperative and early trends in postoperative serum thyroglobulin antibody levels among patients with papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis
Siyuan Xu, Hui Huang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
Endocrine.2022; 80(2): 392. CrossRef
What has changed in the last 20 years in the postoperative specimen findings of the papillary thyroid cancer cases? A retrospective analysis
Burak Bakar, Pınar Taşar, Turkay Kırdak, Sadık Kılıçturgay
Turkish Journal of Surgery.2022; 38(4): 345. CrossRef
A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto's thyroiditis to predict central lymph node metastasis
Wanjun Zhao, Linye He, Jingqiang Zhu, Anping Su
Clinical Endocrinology.2021; 94(2): 310. CrossRef
The Association of Histologically Proven Chronic Lymphocytic Thyroiditis with Clinicopathological Features, Lymph Node Metastasis, and Recurrence Rates of Differentiated Thyroid Cancer
Berna İmge Aydoğan, Adile Begüm Bahçecioğlu Mutlu, Seher Yüksel, Sevim Güllü, Rıfat Emral, Özgür Demir, Mustafa Şahin, Vedia Tonyukuk Gedik, Demet Çorapçıoğlu, Serpil Dizbay Sak, Murat Faik Erdoğan
Endocrine Pathology.2021; 32(2): 280. CrossRef
Beneficial autoimmunity improves cancer prognosis
Laurence Zitvogel, Claude Perreault, Olivera J. Finn, Guido Kroemer
Nature Reviews Clinical Oncology.2021; 18(9): 591. CrossRef
Influence Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: Hashimoto’s Thyroiditis Has a Weak Effect on Central or Lateral Lymph Node Metastasis
Liguang Zhou, Gang Chen, Lei Sheng, Nan Liu, Bin Zhang, Qingdong Zeng, Bo Chen
Cancer Management and Research.2021; Volume 13: 3953. CrossRef
Implications of a background of Hashimoto’s thyroiditis on the current conservative surgical trend towards papillary thyroid carcinoma
Shadi Hamouri, Sohail Bakkar, Almoutuz Aljaafreh, Mohammed Bani Hani, Hussein Heis, Ghazi Qasaimeh, Nasr Alrabadi, Wisam Al Gargaz, Haitham Odat, Yazan Alkurdi, Tarek Manasreh, Mohammad Matalka, Moamin Badwan
Updates in Surgery.2021; 73(5): 1931. CrossRef
Thyroid nodules in childhood‐onset Hashimoto's thyroiditis: Frequency, risk factors, follow‐up course and genetic alterations of thyroid cancer
Yun Jeong Lee, Yeon Jin Cho, You Joung Heo, Eun‐Jae Chung, Young Hun Choi, Jong‐Il Kim, Young Joo Park, Choong Ho Shin, Young Ah Lee
Clinical Endocrinology.2021; 95(4): 638. CrossRef
Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
JAMA Network Open.2021; 4(7): e2118526. CrossRef
The Effects of Chronic Lymphocytic Thyroiditis on Clinicopathologic Factors in Papillary Thyroid Cancer
Davut Sakiz, Muhammed Erkam Sencar, Murat Calapkulu, Ilknur Ozturk Unsal, Levent Aktas, Bekir Ucan, Mustafa Ozbek, Erman Cakal
Endocrine Practice.2021; 27(12): 1199. CrossRef
Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto’s Thyroiditis
Xiao-xiong Gan, Ya-yi Li, Si-jin Li, Shi-sen Mo, Jian-hua Feng, Fei Shen, Wen-song Cai, Ye-qian Lai, Bo Xu
Frontiers in Oncology.2021;[Epub] CrossRef
Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model
Fabiana Pani, Yoshinori Yasuda, Giulia Di Dalmazi, Paulina Chalan, Kathleen Gabrielson, Luigi Adamo, Elena Sabini, Stefano Mariotti, Patrizio Caturegli
Endocrinology.2021;[Epub] CrossRef
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Juliette Paillet, Céleste Plantureux, Sarah Lévesque, Julie Le Naour, Gautier Stoll, Allan Sauvat, Pamela Caudana, Jimena Tosello Boari, Norma Bloy, Sylvie Lachkar, Isabelle Martins, Paule Opolon, Andrea Checcoli, Agathe Delaune, Noémie Robil, Pierre de l
Journal of Experimental Medicine.2021;[Epub] CrossRef
Papillary Thyroid Cancer Prognosis: An Evolving Field
Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvator
Cancers.2021; 13(21): 5567. CrossRef
Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables
Servet KOCAÖZ, Gülay TURAN
Düzce Tıp Fakültesi Dergisi.2021; 23(3): 252. CrossRef
Correlation Between Hashimoto's Thyroiditis–Related Thyroid Hormone Levels and 25-Hydroxyvitamin D
Guanqun Chao, Yue Zhu, Lizheng Fang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma
Dongbin Ahn, Gil J. Lee, Jin H. Sohn, Jae H. Jeon
Head & Neck.2020; 42(5): 1004. CrossRef
Suspicious ultrasound characteristics correlate with multiple factors that predict central lymph node metastasis of papillary thyroid carcinoma: Significant role of HBME-1
Li Jianming, Liu Jibin, Qian Linxue
European Journal of Radiology.2020; 123: 108801. CrossRef
Unexpected high‐risk pathologic features following thyroidectomy in the chinese immigrant population
Arvind K. Badhey, Erin Moshier, Ameya Jategaonkar, Anni Wong, Kristen Echanique, Raymond L. Chai
The Laryngoscope.2020; 130(7): 1844. CrossRef
Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links
Oksana Sulaieva, Oleksii Selezniov, Dmytro Shapochka, Nataliia Belemets, Oleksandr Nechay, Yelizaveta Chereshneva, Dibakhan Tsomartova, Marina Ivanova
Heliyon.2020; 6(1): e03077. CrossRef
Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis
Na Zhao, Xin Liu, Chao Wu, Yuanchao Liu, Xiangnan Zhao, Xianghui He
Journal of International Medical Research.2020; 48(4): 030006052091922. CrossRef
Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis
Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa'a Al-Dayini, Sajjad Karim, Sherin Bakhashab, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Mag
PLOS ONE.2020; 15(6): e0234566. CrossRef
Hashimoto's thyroiditis as a risk factor for thyroid cancer
Ulla Feldt-Rasmussen
Current Opinion in Endocrinology, Diabetes & Obesity.2020; 27(5): 364. CrossRef
Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Brafv600e Mutation: A Single Center Study of 1,207 Chinese Patients
Shuai Xue, Li Zhang, Peisong Wang, Jia Liu, Yue Yin, Meishan Jin, Liang Guo, Yuhua Zhou, Guang Chen
Frontiers in Endocrinology.2019;[Epub] CrossRef
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy
Francesca Ragusa, Poupak Fallahi, Giusy Elia, Debora Gonnella, Sabrina Rosaria Paparo, Claudia Giusti, Leonid P. Churilov, Silvia Martina Ferrari, Alessandro Antonelli
Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(6): 101367. CrossRef
Características anatomopatológicas del carcinoma papilar de tiroides en especimenes con y sin tiroiditis linfocitica crónica.
Carlos Osorio Covo, Jorge Ballestas Barrera, Jorge Martínez Castro, Zully Acevedo Meza, Diego Barrios Castellar, Francisco Herrera Sáenz, Cesar Redondo Bermúdez, Katherine Redondo De Oro
Revista Ciencias Biomédicas.2019; 8(2): 32. CrossRef

Thyroid
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea: Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung; Endocrinol Metab. 2018;33(2):287-295. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.287

5,400 View
58 Download
31 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Background

Most patients with differentiated thyroid cancer (DTC) have a favorable prognosis. However, patients with DTC and initial distant metastasis have not been commonly found, and their clinical characteristics have seldom been reported. In this study, we analyzed the clinical features and prognosis of patients with DTC and initial distant metastasis in Korea.

Methods

We retrospectively reviewed the clinical data of 242 patients with DTC and initial distant metastasis treated from 1994 to 2013, collected from five tertiary hospitals in Korea.

Results

The patients' median age was 51 years, and 65% were women. They were followed for a median of 7 years. Lung was the most common site of distant metastasis: only lung 149 patients (62%), only bone 49 (20%), other single site one (pleura), and combined sites 43 (40 were lung and bone, two were bone and other site, and one was lung and other site). At the time of diagnosis, 50 patients (21%) had non-radioactive iodine (RAI) avidity. Five-year disease-specific survival (DSS) was 85% and 10-year DSS was 68%, which were better than those in previous studies. After multivariate analysis, old age, male sex, metastatic site, and histologic type (follicular type) were significant factors for poor prognosis. However, negative RAI avidity status was not a significant prognostic factor after adjusting for other variables.

Conclusion

The prognosis of Korean patients with DTC and initial distant metastasis was better than in previous studies. Old age, male sex, metastasis site, and histologic type were significant prognostic factors.

Citations

Citations to this article as recorded by

Case report: A case of hyperthyroidism secondary to bone metastasis of differentiated thyroid cancer
Tingyu Gu, Zhihong Zhao, Yuanyuan Shi, Zhenhua Sun, Yao Wang, Zhiyuan He, Kun Wang
Frontiers in Oncology.2024;[Epub] CrossRef
Theranostics of Thyroid Cancer
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
Seminars in Nuclear Medicine.2024;[Epub] CrossRef
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
Cancers.2023; 15(9): 2510. CrossRef
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
Petra Petranović Ovčariček, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Cancers.2023; 15(17): 4290. CrossRef
Differentiating pulmonary metastasis from benign lung nodules in thyroid cancer patients using dual-energy CT parameters
Taeho Ha, Wooil Kim, Jaehyung Cha, Young Hen Lee, Hyung Suk Seo, So Young Park, Nan Hee Kim, Sung Ho Hwang, Hwan Seok Yong, Yu-Whan Oh, Eun-Young Kang, Cherry Kim
European Radiology.2022; 32(3): 1902. CrossRef
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
Hsi-Chen Tsai, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, Miaw-Jene Liou
Diagnostics.2022; 12(1): 221. CrossRef
Long-Term Quality of Life (5-15 Years Post-Thyroidectomy) of Thyroid Carcinoma Patients in Two Tertiary Care Hospitals
Mohammed Yousef Alyousef, Mohammed Khaled Ghandour, Mohammed Al-Mohawes, Mosaad Alnwaisir, Tahera Islam, Khalid Al Qahtani
Cureus.2022;[Epub] CrossRef
Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition
Pınar Celepli, İrem Bigat, Sefika Karabulut, Salih Celepli, Sema Hücümenoğlu
Annals of Diagnostic Pathology.2022; 59: 151973. CrossRef
Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria
Yu Liang, Xingxiang Huang, Zhe Song, Yang Yang, Ju Lei, Mei Ren, Li Tan, Hui Zhang, Francis Moore
PLOS ONE.2022; 17(6): e0269994. CrossRef
Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report
Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli
World Journal of Obstetrics and Gynecology.2022; 11(3): 33. CrossRef
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Juan Antonio Vallejo Casas, Marcel Sambo, Carlos López López, Manuel Durán-Poveda, Julio Rodríguez-Villanueva García, Rita Joana Santos, Marta Llanos, Elena Navarro-González, Javier Aller, Virginia Pubul, Sonsoles Guadalix, Guillermo Crespo, Cintia Gonzál
European Thyroid Journal.2022;[Epub] CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
Evert F S van Velsen, Merel T Stegenga, Folkert J van Kemenade, Boen L R Kam, Tessa M van Ginhoven, W Edward Visser, Robin P Peeters
The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e457. CrossRef
Usefulness of a 3D‐Printed Thyroid Cancer Phantom for Clinician to Patient Communication
Dayeong Hong, Sangwook Lee, Taehun Kim, Jung Hwan Baek, Won Woong Kim, Ki‐Wook Chung, Namkug Kim, Tae‐Yon Sung
World Journal of Surgery.2020; 44(3): 788. CrossRef
Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2020; 30(3): 418. CrossRef
Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
Endocrine.2020; 70(2): 280. CrossRef
Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
PLOS ONE.2020; 15(8): e0238207. CrossRef
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Thyroid.2019; 29(12): 1804. CrossRef
Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
Xin-Yun Zhang, Jian-Wen Sun, Zhong-Ling Qiu, Yang Wang, Xiao-Yue Chen, Jin-Hua Zhao, Quan-Yong Luo
Endocrine.2019; 66(2): 254. CrossRef
Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis
Nilma Malik, Alyaksandr V. Nikitski, Elie Klam, Jason Hunt, Benjamin Witt, Barbara Chadwick, Yuri E. Nikiforov, Devaprabu Abraham
Endocrine Practice.2019; 25(12): 1255. CrossRef
Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Scientific Reports.2019;[Epub] CrossRef
Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano
Endocrine.2019; 65(3): 630. CrossRef
The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study
Young Ki Lee, Daham Kim, Dong Yeob Shin, Cho Rok Lee, Eun Jig Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Annals of Surgical Oncology.2019; 26(7): 2200. CrossRef
Risk Factors for Distant Metastasis in Follicular Thyroid Carcinoma in Korea
Shin Dol Jo, Joon-Hyop Lee, Suk Ha Kang, Yun Yeong Kim, Yong Soon Chun, Heung Kyu Park, Sang Tae Choi, Jin Mo Kang, Yoo Seung Chung
Journal of Endocrine Surgery.2019; 19(1): 1. CrossRef
Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis
Houwei Zhu, Yanqing Qu
Oncology Letters.2019;[Epub] CrossRef
甲状腺腫瘍治療の最新情報

Nippon Jibiinkoka Gakkai Kaiho.2018; 121(11): 1336. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef

Clinical Study
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease: Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(2):300-310. Published online April 25, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.300

4,933 View
86 Download
20 Web of Science
19 Crossref

Abstract PDF PubReader

Background

Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD withdrawal to predict relapse.

Methods

This retrospective study enrolled patients with Graves disease who were treated with ATDs and whose serum thyroid-stimulating hormone levels were normal after receiving low-dose ATDs. ATD therapy was stopped irrespective of TRAb positivity after an additional 6 months of receiving the minimum dose of ATD therapy. Patients were followed using thyroid function tests and TSAb (TSAb group; n=35) or TBII (TBII group; n=39) every 3 to 6 months for 2 years after ATD withdrawal.

Results

Twenty-eight patients (38%) relapsed for a median follow-up of 21 months, and there were no differences in baseline clinical characteristics between groups. In the TSAb group, relapse was more common in patients with positive TSAb at ATD withdrawal (67%) than patients with negative TSAb (17%; P=0.007). Relapse-free survival was shorter in TSAb-positive patients. In the TBII group, there were no differences in the relapse rate and relapse-free survivals according to TBII positivity. For predicting Graves disease relapse, the sensitivity and specificity of TSAb were 63% and 83%, respectively, whereas those of TBII were 28% and 65%.

Conclusion

TSAb at ATD withdrawal can predict the relapse of Graves hyperthyroidism, but TBII cannot. Measuring TSAb at ATD withdrawal can assist with clinical decisions making for patients with Graves disease.

Citations

Citations to this article as recorded by

Analysis of Related Factors in Refractory Graves’ Disease
鑫王
Advances in Clinical Medicine.2023; 13(08): 13439. CrossRef
Interpretation of Thyroid Autoantibodies in Hyperthyroidism
Han-Sang Baek, Dong-Jun Lim
The Korean Journal of Medicine.2023; 98(3): 132. CrossRef
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
Endocrinology and Metabolism.2023; 38(3): 338. CrossRef
Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
Tiago Da Silva Santos, José Carlos Oliveira, Cláudia Freitas, André Couto de Carvalho
Cureus.2022;[Epub] CrossRef
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
Journal of the Endocrine Society.2022;[Epub] CrossRef
Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy
Shiro Watanabe, Shozo Okamoto, Kazumasa Akikawa, Noriyuki Miyamoto, Miyuki Okamura-Kawasaki, Yuko Uchiyama, Junki Takenaka, Takuya Toyonaga, Kenji Hirata, Kohsuke Kudo
Annals of Nuclear Medicine.2022; 36(11): 923. CrossRef
The relationship between atherosclerotic disease and relapse during ATD treatment
Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinology and Metabolism.2021; 36(3): 491. CrossRef
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
Yulin Zhou, Mengxi Zhou, Yicheng Qi, Weiqing Wang, Xinxin Chen, Shu Wang
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110449. CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
Graves' Disease: Can It Be Cured?
Wilmar M. Wiersinga
Endocrinology and Metabolism.2019; 34(1): 29. CrossRef
Medical Treatment of Graves' Disease
Hyun-Kyung Chung
International Journal of Thyroidology.2019; 12(2): 79. CrossRef
When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
Suyeon Park, Eyun Song, Hye-Seon Oh, Mijin Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Doo Man Kim, Won Bae Kim
Endocrine.2019; 65(2): 348. CrossRef
Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
Jianhui Li, Xiaohua Sun, Danzhen Yao, Jinying Xia
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917. CrossRef
Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi, Won Sang Yoo
Endocrinology and Metabolism.2017; 32(2): 281. CrossRef
The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
Thyroid.2017; 27(4): 491. CrossRef
The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
International Journal of Thyroidology.2017; 10(2): 77. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef

First
Prev
Page of 2
Next
Last

Search